H. Koyuncu

Ankara Numune Training and Research Hospital, Engüri, Ankara, Turkey

Are you H. Koyuncu?

Claim your profile

Publications (6)26.53 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: This study evaluated the effect of correction of serum cholesterol levels on erectile function and sildenafil treatment in patients with erectile dysfunction who have only hypercholesterolaemia as a risk factor for erectile dysfunction. Twenty-five patients with a single risk factor (hypercholesterolaemia, serum cholesterol > 200 mg/dl) for erectile dysfunction were included in the study. The patients were recommended to take sildenafil (minimum two 100 mg tablets/week) 1 h before sexual intercourse for 4 weeks. After 1 month washout period, the patients received a single dose of atorvastatin 10 mg/day for 1 month. Similarly, after a 1 month washout period, atorvastatin 10 mg/day and sildenafil (minimum two 100 mg tablets/week) were administered for 1 month as combination therapy. Erectile function was evaluated before and after all treatment regimens using the International Index of Erectile Function (IIEF). Following each treatment modality mean IIEF scores were significantly higher than baseline IIEF scores (p < 0.01). The IIEF score after sildenafil treatment was significantly higher than in the atorvastatin treatment group (p < 0.01); and the IIEF score after combined treatment was significantly higher than in the sildenafil and atorvastatin treatment groups. Correction of serum cholesterol levels with atorvastatin could improve erectile function in patients who have only hypercholesterolaemia as a risk factor for erectile dysfunction. Furthermore, atorvastatin could improve sildenafil's effects on erectile function in hypercholesterolaemic patients with erectile dysfunction.
    Scandinavian Journal of Urology and Nephrology 03/2008; 42(5):437-40. DOI:10.1080/00365590801950279 · 1.24 Impact Factor
  • Cuneyt Ozden · Ozdem Levent Ozdal · Suleyman Bulut · Ozer Guzel · Hasbey Hakan Koyuncu · Ali Memis ·
    [Show abstract] [Hide abstract]
    ABSTRACT: In recent years serum inhibin B level has been proposed as a major indicator for Sertoli cell function and spermatogenesis. This study evaluated the effect of varicocelectomy on serum inhibin B levels and semen parameters in infertile patients with varicocele. Thirty consecutive patients with varicocele who were complaining of infertility with oligoasthenospermia on sperm analysis were included in the study. All the patients underwent subinguinal varicocelectomy. Spermogram, serum inhibin B levels and hormone analysis were performed at 6-month postoperative follow-up. The mean age of the patients was 24.06+/-3.6 years. There was no statistically significant difference between the mean serum follicle-stimulating hormone, luteinizing hormone, prolactin and testosterone levels of the patients before and after the treatment (p > 0.05). There was a statistically significant improvement in sperm concentration, forward progressive motility and serum inhibin B levels after the treatment (p < 0.05). Serum inhibin B level as an endocrine marker combined with a spermogram could provide efficient data for evaluating the effect of varicocelectomy on spermatogenesis.
    Scandinavian Journal of Urology and Nephrology 01/2008; 42(5):441-3. DOI:10.1080/00365590802028141 · 1.24 Impact Factor
  • S. Gokkaya · C. Özden · L. Ozdal · H. Koyuncu · O. Guzel · A. Memis ·

    European Urology Supplements 03/2007; 6(2):261-261. DOI:10.1016/S1569-9056(07)60951-8 · 3.37 Impact Factor
  • C. Ozden · L. Ozdal · S. Bulut · O. Guzel · H. Koyuncu · A. Memis ·

    European Urology Supplements 03/2007; 6(2):289-289. DOI:10.1016/S1569-9056(07)61063-X · 3.37 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate the relationship between metabolic syndrome and annual prostatic growth rates in benign prostatic hyperplasia (BPH) patients. The 78 BPH patients with lower urinary tract symptoms included in this prospective study were divided into two groups according to whether they had a diagnosis of metabolic syndrome. This diagnosis was made according to the most recent consensus report of the National Cholesterol Education Program's Third Adult Treatment Panel. Blood pressure, body weight, body height, and waist and hip circumferences were measured. The body mass index (BMI) and waist-to-hip ratio (WHR) were calculated. Biochemical analyses including serum glucose, total cholesterol, triglycerides, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), insulin, and prostate-specific antigen (PSA) were performed. Total prostate (TP) volume and transitional zone (TZ) volume were measured by transrectal ultrasound. Annual TP and TZ growth rates were calculated. BPH patients with metabolic syndrome (first group) had significantly higher median body weight, BMI, serum glucose, serum triglyceride, and PSA levels but lower serum HDL-C level, compared with BPH patients without metabolic syndrome (second group, p<0.05). Median annual TP growth rate (1.0 ml/yr) and median annual TZ growth rate (1.25 ml/yr) were significantly higher in the first group versus the second group (0.64 ml/yr and 0.93 ml/yr, respectively, p<0.05). The present study demonstrates a further increase in prostate growth in BPH patients with metabolic syndrome. Future studies are needed to confirm our results and to explain underlying mechanisms.
    European Urology 02/2007; 51(1):199-203; discussion 204-6. DOI:10.1016/j.eururo.2006.05.040 · 13.94 Impact Factor
  • L. Özdal · C. Özden · K. Benli · S. Gökkaya · H. Koyuncu · A. Memis ·

    European Urology Supplements 03/2005; 4(3):188-188. DOI:10.1016/S1569-9056(05)80746-8 · 3.37 Impact Factor